Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome
- PMID: 34876325
- DOI: 10.1016/j.eururo.2021.11.013
Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome
Abstract
To determine the incidence of renal neoplasia among patients undergoing nephrectomy for polycystic kidney disease (PKD), we queried our institutional nephrectomy registry (years 2000-2020). Approximately 4% (231 of 5757) of patients who underwent nephrectomy had PKD, and 26 of these 231 patients (11.3%) had renal neoplasia. Tumors from an additional two patients with PKD were also evaluated. Patients with PKD who had tuberous sclerosis complex (TSC)-associated renal neoplasia were screened for PKD1/TSC2 contiguous gene deletion syndrome (CGS) using single nucleotide polymorphism arrays. The median age of patients with PKD and renal neoplasia at nephrectomy was 54 yr. The median tumor size was 2.0 cm and the tumors were predominantly of low grade and stage. The tumors consisted of 23 renal cell carcinomas (RCCs), one epithelioid angiomyolipoma, and four angiomyolipomas. The median follow-up was 59.5 mo (n = 26) and only one patient with clear cell RCC developed metastases. Two patients with angiomyolipomas had PKD1/TSC2 CGS. Our results support screening of patients with PKD and TSC-associated renal neoplasia as well as TSC patients with cystic renal disease for CGS, as identification of patients with CGS can better define the manifestation and prognosis of CGS and guide counseling regarding patterns of inheritance. PATIENT SUMMARY: We identified patients with abnormal kidney cell growth (called renal neoplasia) among those undergoing removal of kidney tissue for polycystic kidney disease (PKD) and patients with a syndrome involving deletions in two genes, called PKD1/TSC2 contiguous gene deletion syndrome (CGS) at our institution. Of 231 PKD patients with removal of kidney tissue, 11.3% had renal neoplasia, and two patients with angiomyolipoma tumors had PKD1/TSC2 CGS. Detection of renal neoplasia associated with a condition called tuberous sclerosis complex in PKD may increase the identification of patients with PKD1/TSC2 CGS and guide patient counseling regarding outcomes and patterns of inheritance.
Keywords: PKD1/TSC2 contiguous gene deletion syndrome; Polycystic kidney disease; Tuberous sclerosis complex.
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Reply to Yang Zhao, Wenda Wang, and Yushi Zhang's Letter to the Editor re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229-33.Eur Urol. 2022 Oct;82(4):e117. doi: 10.1016/j.eururo.2022.06.022. Epub 2022 Jul 7. Eur Urol. 2022. PMID: 35810047 No abstract available.
-
Re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229-33.Eur Urol. 2022 Oct;82(4):e116. doi: 10.1016/j.eururo.2022.05.039. Epub 2022 Jul 7. Eur Urol. 2022. PMID: 35810048 No abstract available.
Similar articles
-
Atypical noncontiguous TSC2/PKD1 gene deletions presenting as tuberous sclerosis/polycystic kidney disease contiguous gene syndrome.Am J Med Genet A. 2024 Dec;194(12):e63830. doi: 10.1002/ajmg.a.63830. Epub 2024 Aug 2. Am J Med Genet A. 2024. PMID: 39095963
-
TSC2/PKD1 contiguous gene syndrome, with emphasis on a case with an atypical mild polycystic kidney phenotype and a novel genetic variant.Nefrologia (Engl Ed). 2020 Jan-Feb;40(1):91-98. doi: 10.1016/j.nefro.2019.03.003. Epub 2019 Jun 5. Nefrologia (Engl Ed). 2020. PMID: 31176519 English, Spanish.
-
TSC2/PKD1 Contiguous Gene Deletion Syndrome: A Case Series.Am J Kidney Dis. 2025 Sep;86(3):353-359.e1. doi: 10.1053/j.ajkd.2025.05.004. Epub 2025 Jun 17. Am J Kidney Dis. 2025. PMID: 40553952
-
Lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas, and renal cell carcinoma.Hum Pathol. 2022 Nov;129:123-139. doi: 10.1016/j.humpath.2022.09.001. Epub 2022 Sep 14. Hum Pathol. 2022. PMID: 36115585 Review.
-
Renal disease in tuberous sclerosis complex: pathogenesis and therapy.Nat Rev Nephrol. 2018 Nov;14(11):704-716. doi: 10.1038/s41581-018-0059-6. Nat Rev Nephrol. 2018. PMID: 30232410 Review.
Cited by
-
Prevalence of Renal Neoplasia in Autosomal Dominant Polycystic Kidney Disease: Systematic Review and Meta-Analysis.Nephron. 2024;148(7):457-467. doi: 10.1159/000536245. Epub 2024 Feb 1. Nephron. 2024. PMID: 38301614 Free PMC article.
-
Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China.Orphanet J Rare Dis. 2022 Jul 23;17(1):288. doi: 10.1186/s13023-022-02443-1. Orphanet J Rare Dis. 2022. PMID: 35870981 Free PMC article. Review.
-
Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.Cancers (Basel). 2023 Aug 10;15(16):4043. doi: 10.3390/cancers15164043. Cancers (Basel). 2023. PMID: 37627070 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical